Good morning, everyone. My name is John Heardink, and welcome to our Tribe Public CEO presentation titled Ebola, Marburg, Antivirus, Impox, and Beyond, Building a Resilient Infectious Disease Portfolio Preparedness Strategy. The presentation will be co-hosted by David Dodd, Chairman and CEO of Geovax Labs, trades on the NASDAQ under the symbol GeoVX, and is targeted to last about 30 minutes today. Geovax Labs is a clinical stage biotechnology company focused on developing vaccines and immunotherapies that address high-consequence infectious diseases and solid tumor cancers. Geovax's priority program is GeoMVA, a modified Vaccina and Cara MVA-based vaccine targeting impacts in smallpox. As many of you know, I am the managing member of Tribe Public. Our website is tribepublic.com, T-R-I-B-E-P-U-B-L-I-C.com. Members from over 35 countries and all 50 states have joined Tribe Public freely to gain direct corporate access to leaders and experts they care about via our webinar events, like today, and via 41 venue sites located across the U.S. where we host in-person events over luncheons, dinners, and speaking engagements with local Tribe members. Tribe members, furthermore, are invited to submit names of experts and leaders of industry via our free wish list process at our website, adding names of companies and subjects that span across all sectors so they can learn more. Please note, I am also the managing director of Vista Partners, LLC, a registered investment advisory firm in California, and its website is vistapglobal.com. That's B-I-S-T-A-P-G-L-O-B-A-L.com. Please review both sets of disclaimers at each site and know that I'm currently a shareholder of Geovacs and at times I've been advisor to Geovacs. I would also like to thank you all for participating and for all of your questions you have submitted and remind you all that you may send in more questions via the Zoom chat feature during this event and we'll do our best to get to many of them. A video of this event will also be published on our TriPublic YouTube channel and be sent out to all post this event via the Tribe This Week, which is our weekly e-newsletter that goes at the end of each week. Thank you all also to Geovax Labs for joining us today. Now let's get started. We have, again, David Dodd, Chairman and CEO. David, could you start with just giving us a little bit of your background and then begin your presentation?
Sure, John, and thank you for this opportunity. And I also want to not only welcome, but thank all members of the tribe, tribe public, as well as others who are participating in today. Hopefully you'll learn a little bit, become interested in Geovax, and want to do a little bit of follow-up, and I look forward to that. Just to get started, let me just mention that my own background is 40 plus years within the pharmaceutical vaccine industry. It's a wonderful industry in which to build a career, provides a tremendous amount of opportunity. And what we're talking about today is one of the reasons why I've always advocated that younger people starting their career consider this industry. And that is it presents continuous challenges. I mean, just think back to when we were all much younger, 40 plus years ago, when we started hearing about something called AIDS. it wasn't even called that there was some new disease no so they're always within our industry the opportunities for and the need for innovation for development on an individual basis on an organizational basis and it's quite an exciting industry there are winners and losers of course but it's a great industry in which to build one's career and so i i've had the uh the good fortune of uh starting very young and continuing to stay in this industry and work with it across many different opportunities. I would encourage anyone else to consider that. So we are facing today a global challenge, but this global challenge is not new. It does seem that it's happening more quickly, and that is that emerging viral threats tend to test our limits of capability to be able to respond locally as well as globally, and that continues to become perhaps an even greater challenge because as the world in essence gets smaller we travel much more and all we are seeing that emerging viral threats in fact emerging pathogenic threats are happening it seems like more frequently they migrate much faster and we have to figure out ways to be able to respond to those but even more importantly in response is really preparation and being prepared is what is most important for us. And so we've entered this persistent outbreak era. It was just a few weeks ago. Last month, we were talking about Hantavirus. And Ebola was frankly not on our mind, certainly not in the United States, but then certainly starting within earlier this month, we started hearing about these outbreaks in Democratic Republic of the Congo, in Uganda of some new type of strain we'd never heard about and what was going on there. But let's think about what we've been dealing with just within the recent past. We've been talking about what was originally monkeypox. We first started talking about that four years ago in 2022. Then it became known as M-pox. But more importantly, it went from an initial strain to a more virulent strain. And now we have a new combination strain. We're seeing the first initial cases in the U.S. from that. Then we have the Bundabujo or the BDBV Ebola outbreak. That's the third version of the Ebola virus family that we've dealt with. Four, if you want to include Marburg. And as I mentioned earlier, we were talking just recently about antivirus. Now, these are all things that provide tremendous amount of not only concern, but threats. What's happening starting probably next week? Well, what's happening next week is we're going to start seeing millions of people come to the United States for the World Cup. And when people are traveling as frequently as we do today, globally, throughout the world, what we're doing is we may not think about it, but we're carrying viruses with us. Most of us have pretty good immune systems, so we don't have to deal with that. But that threat increases tremendous exposure and threats on a global basis. How we deal with those and how we can be prepared to deal with those becomes critically important. And it's preparedness that is more important than simply response. We respond when we're in the middle, the eye of the hurricane, the middle of a threat. But we need to be preparing for in-between crises. And that we have much to continue to learn. Now, MVA, John mentioned we use a technology called Modified Vaccinia Ankara. MVA is the name of what was originally developed as the smallpox vaccine. It enabled us to eliminate smallpox from the world because previously we used to use vaccinia. Unfortunately, vaccinia, which is still around today, is contraindicated in certain populations. pregnant women, children, and people with compromised immune systems. We never would have eradicated the world of smallpox had we not developed a new version of it, which was good and it was safe for all populations and yet maintains a very robust immune response against smallpox in this case, or what we could call pox viruses. Well, that became critically important. It worked, It goes back to the last case of smallpox was announced in October of 1977. It was declared eradicated in 1980 because there had not been any more cases since that 1977 last case. And then we repurposed MVA beyond being simply a vaccine in terms of being a platform because it does not replicate in humans. It's exquisitely safe. It allows us the inclusion of multiple parts of a virus, so it's known as a multi-antigen vaccine, which means you can take various components of pathogens. Even you can speculate about doing a single vaccine that would integrate Ebola Zaire, Ebola Sudan, Ebola BDBV, and Ebola even Marburg. All of these are very, very threatening, highly fatal. They have fatality rates up to 95%. The latest one has one of approximately 40%, but being able to put all those into a single vaccine and being able to deal with that. You can't do that with mRNA. You can't do that with other types of technologies such that AstraZeneca utilizes an adenovirus vector, different versions of that. Can't do it with the protein adjuvant types of technology such as Novavax does. They can do a combination, but they can't integrate it into one. You have the opportunity. It's very challenging, but the opportunity to do it with MVA. So that type of platform enables you to take a single platform and address multiple outbreak opportunities and to do that in preparation, not simply in response. So the core problem that drives everything is the supply chain. People think it's about just developing something that within the lab seems to work. That's great. But if you can't manufacture it, keep it stable, ship it, be able to utilize it, not in a highly frozen state, but in a real-time, administer it wherever it needs to be. Villages in Africa, villages in the Asia-Pacific region, in the Southern Hemisphere where many of these emerging pathogens, we see the outbreaks. If you can't do it in those delivering millions and millions, hundreds of millions of doses if necessary, then all you have is a science project. And far too often, we have something that's exciting in the lab. It may even show that in a well-developed nation with all the access to supply chain elements, such as the United States or in parts of Europe, frozen state delivery, that it works, that's great. No, go into the real world. What are these people doing today in Uganda, in the Democratic Republic of the Congo, the DRC? They are going from village to village, highly exposed, dealing with a highly contagious. In this case, the latest one being 40 percent plus in terms of fatal. But if you go to certain strains of the Ebola virus family, the filovirus family, you're dealing with 95 percent. In those cases, if you cannot give people and administer successfully, it doesn't matter how well it might work in the United States, throughout the developed world, so to speak, it's not going to help them. And we're going to have devastation. And that will not simply stay in that location, that geography. It will travel. Because as people travel more and more, coming to the World Cup, coming to other types of travel, they will be carrying that. That's what we're seeing already within POX. And we've seen it previously with other parts of the of the Ebola family. We have to get away from that. So I'm going to talk about a product that is is close to initiating a phase three trial. It's called GEO MVA. That is the MVA vaccine that is the version from GEOVAC. It's tied in with a global preparedness program. The initial indication, the vaccine for which a phase three, pivotal phase three trial is scheduled to start in fourth quarter of this year is to target M-pox as well as smallpox. It's very important because today there is a limited, insufficient supply of MVA vaccine in the world. The European Medicines Agency, or EMA, the EU equivalent of the FDA, has provided GFX an expedited pathway for development. They have waived our having to do the traditional phase one and phase two clinical trials in humans. They're only requiring a phase three trial in healthy adults that will compare the immune response of our version of MVA with that of the only supplied product worldwide today, which is from a company out of Denmark known as Bavarian Nordic. And they're doing that because our MVA and that of Bavarian Nordic were initially derived from the same parental cell line. They are about as close as one could get and being, for all intents and purposes, identical. And we're targeted to start that trial in fourth quarter. And the reason why the EMA has done that is, first of all, because the extreme safety of MVA in general, but more importantly, the relationship between our MVA and that of Bavarian Nordic. So we have genetically sequenced our version of it and shown that it matches up 100% with all of what are known as the regions of interest or ROI that the regulatory authorities look at. So because of that, they've given us an expedited pathway. We will initially be conducting a 500-patient trial. It'll be healthy adults, 250 on our vaccine, 250 on the MVABN vaccine. We'll be looking at two endpoints. One will be neutralizing antibody, and the other will be the seroconversion rate. And that'll be started as we're targeted right now, fourth quarter of 2026. We've already manufactured all the product. It's been packaged in the vials. It's ready to go. We've selected our CRO, our clinical research organization. We've selected where the sites are going to be, and we have it set up so that when the trial starts. It'll be completed with all 500 patients within 12 weeks. That's essentially three months. We'll have the readout of that in the middle of next year, and that will be based upon those two endpoints that I talked about, neutralizing antibody and serial conversion rate. Why are we so confident that we will show non-inferiority, the criteria we've been given that are the basis for registration or marketing authorization is to demonstrate non-inferiority on those two measures of our GEO-MVA to MVABN. And the reason why is we share the same lineage. We have the 100% match with genetic sequencing. We utilize, for all intents and purposes, the same manufacturing process, the same dose, and the route of administration we're following. We have the expedited pathway. We've been waived for phase one, phase two. And with that, we'll be going forward. We feel that with this, we will be able to demonstrate that. If that all works out and we're able to demonstrate that we have non-inferiority on those endpoints, we will then pursue emergency use licensing with the WHO. And we'll also pursue expedited approval with the EMA. And then following that, we will then, while assuming we're granted either EUL or the expedited pathway, we will then be conducting a 3,000 patient safety study that will be 3,000 patients, adults, Not those, no efficacy measures required, just demonstrating that among the 3,000 patients that we will be doing, two-thirds of whom will be in Africa, one-third will be in the EU, that it's a safe product, just further validating what we already know about MVA that does not replicate in humans and there are no adverse events otherwise, maybe a sore at the site of injection. But other than that, we hope to show, which we've shown before in other studies, rather the benign, any types of adverse events or tend to be localized related to the administration of the vaccine. Now, what does preparedness require? It requires manufacturing resilience because right now, if we look at it, there were approximately 7 to 8 million doses of vaccine against M-pox delivered and utilized and administered in 2025. However, there was an unmet need for further MVA vaccine in excess of 15 million doses, 10 million of which were specifically requested out of Africa, another 3 million thereabouts in the EU, and then elsewhere, different contracting agencies, UNICEF and GAVI. We've got strategic stockpiles both across the world. People are not aware of this, but in the U.S., Health Canada, the U.K., Israel, Saudi Arabia, Middle East, throughout Asia Pacific. Most nations have stockpiles primarily developed related to the potential biodefense threat or bioterrorism threat of smallpox, but it's the same vaccine. So it becomes utilized when we have Mpox outbreak. So we're looking for expanded capacity on a global basis, being able to do regional manufacturing and reliable access, not having to just build it when we absolutely need it, but build it on an ongoing basis. It's not just a vaccine story. It's an infrastructure story. And this is what is most important. And the reason why is utilizing something such as the MVA-based platform. It allows us to move forward through cell line manufacturing, moving away from the historical, somewhat very slow and cumbersome manufacturing process. Same process we use, same process that LeBron Nordic uses, but we're migrating to a new process that will be scalable, reduced costs, reduced time to develop a batch. We'll provide a tenfold increase over the current manufacturing process, being able to do twice the number of batches within the same time frame. We can only do one batch today, so we have a multiplier effect, and also doing it at lower cost, and frankly being able to transfer this technology so that it could be localized manufacturing, which is not the case today. So we're excited about it. We hope to be able to transition to that new manufacturing technology within the next three to five years. But we will initially go to market with the same technology that is used to manufacture MVA today. Most important reason is it then provides a reference frame for being able to transition much faster to a new manufacturing process that would be cell line driven and would have those attributes I just mentioned. So why should anybody who's thinking about potentially investing in GeoVax be interested in it? And first of all, I want to encourage you and employ you to do your own due diligence. because there are always things that can trip people up. So our current plan is, and what we're dealing with today, is a very large and expanding market. I mentioned there were around 8 million doses last year. That translated last year into $700 million. That was the Bavarian Nordic product, the traditional vaccinia product with its limitations because of the contraindications. There's also a product out of Japan that also carries those same limitations or contraindications. So the Bavarian Nordic product did approximately $500 million in sales last year and U.S. dollars equivalents. There were around another 100, almost $150 million from the traditional vaccinia product and then about another 50 for the product out of Japan, which is from KM Biologics. Now, in total, that gives you about $700 million in the total market. However, the demand that was requested that could not be met is an additional $1.3 billion. Our focus will be to go after what is being unmet, not to directly compete with someone who's already supplying because what is out there is larger than the entire market that was satisfied last year. So we will be going after that. We've already started discussions with potential contracting agency. We consider this a highly de-risked program because we have the expedited pathway. We've been waived to phase one, phase two trials. We're focused on the immunobridging 500 patient study with a mid-year 2027 readout. And we believe there's a high likelihood of success because of the attributes we've talked about. And although we'll go to market with the current manufacturing, we are focused on moving forward in as timely a manner as possible to this new manufacturing process. And again, I want to emphasize, we're anticipating that will be three to five years. So we'll go to market with what we have for current, for regulatory reasons, important reasons being able to supply. But we will then transition as quickly as we're able to. Now, I want to turn, I want to also comment because we're in the vaccine business. People of the last several years, certainly we've seen more of reluctance from investors and others who might be funding for a vaccine. That seemed to end just the other day with Lilly's announcement of spending approximately $4 billion to acquire three infectious disease-related vaccine players. And that is opening up, and we're starting to hear about it. we're starting to hear inquiries and receive inquiries about it, that it looks like that is turning the corner on the consideration of the vaccine industry, especially for companies who are in late stage development towards registration, such we now find ourselves with our GEO MVA, that that is then providing somewhat of some momentum and interest in there. We anticipate that other large players, not just people already in the vaccine industry, but players that are looking to have sustainable growth opportunities will continue to look at this because vaccines are absolutely critical in addressing emerging threats, especially pathogenic threats, both from a viral infectious disease as well as a bacterial. We're focused on the infectious disease viral standpoint. But again, we consider that a very positive for our industry, for players such as Geovax potentially. It all takes, obviously, people to look at it, become familiar with your technology. Due diligence is not conducted overnight, but we do believe that this is a real boost for those of us in the development stage, especially the late development stage of vaccines. Now, what is the opportunity ahead? Well, what we look at for us is a number of groups are looking at. The Africa CDC is very active, vocal, and in need of instituting the continental-based vaccine capabilities, being able to work with MVA. We've been in discussions with the Africa CDC for the last three years in this. UNICEF and GAVI has an active process underway building stockpile for GEO for products of MVA vaccines, specifically the GM, the MVA standalone vaccines such as GEO MVA. In Europe, HERA is driving the way WHO through the emergency use licensing pathway. In the U.S. under BARDA, HHS, we have a strategic national stockpile. Other such national stockpiles, as I mentioned, we have them in Saudi Arabia, throughout the Middle East. We see it in Israel. We see it throughout in the UK. We see it in Health Canada. We see it in Australia. We see it in Japan. So it's all over the globe. We're seeing that there are stockpiles looking for MVA vaccine and MVA-based vaccine. That is what we are focused on as a company. pipeline optionality. With the recent announcements about the latest outbreak in Ebola, I just want to remind everyone that we have previously successfully developed vaccines against Ebola Zaire. We showed 100% protection in a single dose in that one against Ebola Zaire. Ebola Zaire has up to a 90% fatality rate. We've done Ebola Sudan. We've done Marburg. Marburg, The Angola strain of Marburg has a 95% estimated fatality rate. So we've worked on that. So we've done those three before, presented those at international conferences. We've carried them all the way through non-human primate testing. So we continue to have interactions with government funding agencies and others, such as CEPI or BARDA for the government side. And we'll continue to listen and look at those. We are not currently actively working on the new strain because we are so focused on our GeoMVA to bring that to fruition and to initiate that phase three trial in the fourth quarter. So let me just close and say this is really all about not just one product or not just two products. It's all about what we need to be prepared because preparedness should be done in between crises. Once we're in the middle of one, we're scrambling to try and get something developed. That's what's going on right now. You're seeing a lot of energy, a lot of activity of people trying to address this new strain. They're trying to play catch up. And that's what we intended to do worldwide. Not just one nation, but everyone. And the industry, for the industry to move forward, especially companies, we will consistently be dependent upon the necessary funding that either comes from government agencies or NGOs that have a stake in all of this. And with that and our capabilities, our expertise, our experience, we can move forward and better address such threats from a preparedness standpoint so that when the outbreaks do occur, we're all ready. We already have product manufactured. We already have product distributed. It's ready for administration as necessary. That is what we all need to be seeking. And with that, I'll end my presentation, and I'm happy to take any questions that may arise. And I'll just hold this up in case any of the questions necessitate going back to a previous slide.
Well, thank you again, David. Very, very interesting. And thanks for giving this picture of both how Geovacs and how the world is dealing with these infectious diseases and how we might deal with them in the future. just a couple minutes for questions now one of them was with in regards to funding your company and maybe speak about what you've done recently to push forward the development
sure thank you John and thank you whoever had that question it's a very good and most pertinent question because we are driven by our balance sheet we're pre-revenue which means we have no internal funding mechanism. So we're either dependent on the sale of equity to raise capital or from a non-diluted funding. And we pursue both, as you might imagine. Last week, we had the opportunity. There was a very strong performance of our stock. We traded in excess of 275 million shares, which was over 50 times turnover of our outstanding shares during last week all built upon this ebola outbreak the noise associated with that and the recognition that we sit right in the middle of it and our capabilities it enabled us we were able to take advantage of that we are a micro cap company subject to baby shelf rule etc but we were able to the through the combination of a pipe as well as organic warrant exercises we were able to to bring into our balance sheet in excess of four million dollars last week we continue to have further discussions, and there's also additional warrants out there that will likely be exercised in the near term also given the continued shrink of our stock price. So we'll continue to pursue those, and we're also obviously in touch with non-diluted funding sources, not just U.S. based, but globally based for opportunities to be able to advance our programs forward, especially GOMVA, because that becomes the basis for everything we do as our new platform going forward.
Okay. Thank you, David. Another one is regards to your regulatory pathway. It says GeoVax recently highlighted an expedited regulatory pathway for GeoMBA. Why do you believe that is important? Can you stress that? And are there any milestones ahead of us that you
can highlight as well for it's a critically important um achievement and the milestones are most important and few because we're so close to to initiating that trial we we started in 2022 2023 uh discussions with the ema on the concept of an expedited pathway it would normally take five to seven years to be able to get to at best to get to a phase three trial and we were after two rounds of scientific discussions or advice as they call it the EMA we they accepted our proposal which was to to waive phase one and phase two go directly to to this immunobridging trial you just needing to demonstrate non-inferiority of two immune response measures, not having to do safety and efficacy. And based upon that, if we show non-inferiority, we will then be, it'll be sufficient for authorization and we'll have the same labeling as the MVABN. That is critically important because it moves us to the transformation of a revenue producing company much faster than we otherwise would be changing the whole course of Geovax, which then will be supportive of our entire infectious disease portfolio because everything is built upon MVA, including our current candidate as a single dose MVA, as well as our new manufacturing process. So this is critically important. And from an investment standpoint moves us forward. What are the milestones between now and when we, let's say we get to the data readout in 2027, We're completing right now the necessary work in support of our clinical trial application, which is necessary to start the trial. That'll be completed and submitted by the beginning of September. So as I said, fourth quarter is we then will then go forward. We've already manufactured all of the product. It's all been packaged. We need obviously 500. If you have 250 patients, they have two doses. That's 500 doses. We produced an excess so far of 6,000 doses. We have more than enough product already packaged, released, ready to go. As I mentioned, we have the sites. So the biggest milestone right now is our balance sheet. We continue to be raising money and adding to the balance sheet to be able to go forward because once we initiate that trial, we expect to have the results from it mid-2027, a critically important milestone. That is when we will either announce that we have met the criteria, which we believe we will. But again, we have to get there and demonstrate that, that we've met the criteria for the EMA. Based upon that, we'll then proceed with the formal discussion. We've been doing informal with both WHO and EMA about emergency use licensing, as well as expedited EMA review. And with that, the key will be to raise money to be able to produce additional product going forward, complete that safety database, but prepare for commercialization. we will begin to engage with contracting agencies while we have the immunobridging trial. They've already asked us to start negotiating for contracts, but we've held off until we're into that trial. So those are the timelines. What will it take? We are focused on to be able to have a completion and an authorization. We're looking at less than $20 million that we're focused on raising part of that four million dollar plus that we just uh raised last week contributes to that so uh we're we're on that pathway and we'll continue to focus on that those that's the milestones the activities and the the cost of getting to that point thank you david uh this
is in regards to impacts there was a little confusion apparently a couple folks in regards to the market approximate market size that you believe uh there is for impacts is that 11 billion two billion what is the number that you were suggesting in dollars it's a two billion dollar
market that is broken down that 700 million dollars was what the the sales are estimated that were done last year uh one was from bavarian nordic they did 150 million in u.s equivalent dollars if you convert their danish corona from their annual report so if you convert that then And if you look at what emergent biosolutions delivered, it was somewhere between 120 million to 150 million. So we're using 150 million. And if you look at the KM Biologics from Japan, they did around between 30 and 50 million. We're using 50 million. That adds up to the 700 million. If you convert those back to doses, that's around eight, depending on pricing assumptions you have, that's around eight million doses. but what was actually requested out there was an additional 15 million doses that Africa CDC and others were seeking to buy but there was not and that was all MVA vaccine and so that's what we will be going after if you turn that into a dollar equivalent that's approximately 1.3 billion dollars in opportunity that existed last year in requests for product that could not be fulfilled and that's
what we will be focusing on is that gap. Okay, thank you. And then you've stressed regards to domestic manufacturing. Can you speak to that a bit? Yeah, excellent question,
because currently today there's not a single manufacturer, contract manufacturer, or operating manufacturer in the United States capable of providing product in support of phase three or commercial-grade product. We currently are working with Oxford Biomedica, or OXB. They are based in Oxford, the UK, the manufacturing facility we utilize. They acquired another company a couple years ago. We've been working with that company, but ABL, which is based, they have operations for us for MVA vaccine in Strasbourg, France, and Lyon, France. They also have facilities, OXB does in Boston as well as in North Carolina. So we anticipate that we will be working with, we don't anticipate we'll be working with OXB, but what we'll do is transition as we move forward with the continuous cell line manufacturing I talked about over the next three to five years. We will be transitioning into a U.S. domiciled manufacturing facility that will then provide the first domestic manufacturing, so U.S.-based manufacturing for either phase three or commercial grade products. And it's important to talk about phase three because for future products, we will be doing not just MVA alone, but other products also using MVA. So that'll be based in
the U.S. Okay. Thank you, David. Another question says, what durability of immune responses are you
looking for? Durability of the immune responses. All we have to, well, the durability, the shelf life is typically three years, and we'll be granted that if we meet the non-inferiority. But we have gone back and tested and done tests in either animal models of monkeys, where we went back eight years after they had been vaccinated, and they still maintained the immune response. So it's long-term durability with MVA. That has been recognized. But from stability studies, what will be granted will be what is currently given through the current
manufacturing process, and that'll be three years. Okay, and then what is the anticipated price per dose, and how would this compare with Bavaria Nordics product? Great question, one that I would
not disclose, even if we had, first of all, we don't have that yet, because we're not at that point to have a pricing dose, which is another reason why we wouldn't engage in contract discussions. That'll be worked out between ourselves and our CDMO, OXB. We're working on that now, and it's obviously tremendously assumption-driven. But what we will see as we move forward to the cell line manufacturing process is we see a five-fold cost reduction opportunity there. So we'll be more than competitive. Okay. Well, David, I think we've
exhausted the time we've had with you today, and we appreciate you and GeoVax for joining us and all of the tribe members from around the world, including Seoul, Luxembourg, England, Switzerland, and beyond, and all the U.S. folks across the 50 states. So I want to thank you again for doing that. Remind everyone that we will be publishing a video on our tribe public YouTube channel later today that you can pass on to folks and or review if you've missed something and want to share it with others. And then we'll also include you as you signed in to the tribe this week that'll come out Friday, typically after the close at 115 Pacific here in San Francisco. Thanks again for being part of the tribe, everyone, and then thanks again to David Dodd and Geovax for sharing and getting us up to speed on this situation and also on Geovax. Thank you all, and I look forward to having you on our next event. And if you would like to meet with David personally at any of our 41 event venues across the U.S. and or you want to establish a new one, please contact us at research at trypublic.com. And we'd love to hear your interest or go to the website at trypublic.com and submit it into the wish list section where you would like to like us to host an event. And thanks again, David. Thanks again to all the tribe, and you guys have a great rest of the day, and we'll see you soon.